Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Karunanithi-Ponnusamy"

2 News Found

Alembic Pharma elevates Karunanithi Ponnusamy as President of Animal Health Business
People | May 22, 2026

Alembic Pharma elevates Karunanithi Ponnusamy as President of Animal Health Business

Pharma veteran with over three decades of industry experience to lead Alembic’s animal health growth and market expansion initiatives.

Karunanithi Ponnusamy elevated to President – Animal Health Business at Alembic Pharma
People | May 04, 2026

Karunanithi Ponnusamy elevated to President – Animal Health Business at Alembic Pharma

With over 30 years of pharmaceutical industry experience, Ponnusamy will lead Alembic’s animal health business strategy, market expansion, and operational growth initiatives

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

AngioDynamics gets FDA nod for RELIEF trial to evaluate NanoKnife for enlarged prostate treatment

Apollo Hospitals Seshadripuram expands cardiac care capacity with second Cath Lab

Brooks Instrument launches ultra-compact advanced mass flow controller for research applications

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Packaging